Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
- Authors:
- Tong Yu
- Weibo Jiang
- Yang Wang
- Ying Zhou
- Jianhang Jiao
- Minfei Wu
-
Affiliations: Department of Orthopedics, The Second Norman Bethune Hospital of Jilin University, Changchun, Jilin 130000, P.R. China, Department of Operating Room, The Third Hospital of Qinhuangdao, Qinhuangdao, Hebei 066000, P.R. China - Published online on: February 22, 2024 https://doi.org/10.3892/ijo.2024.5628
- Article Number: 40
-
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Misaghi A, Goldin A, Awad M and Kulidjian AA: Osteosarcoma: A comprehensive review. SICOT J. 4:122018. View Article : Google Scholar : PubMed/NCBI | |
|
Dorfman HD and Czerniak B: Bone cancers. Cancer. 75(1 Suppl): S203–S210. 1995. View Article : Google Scholar | |
|
Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rizzo A, Nannini M, Astolfi A, Indio V, De Iaco P, Perrone AM, De Leo A, Incorvaia L, Di Scioscio V and Pantaleo MA: Impact of chemotherapy in the adjuvant setting of early stage uterine leiomyosarcoma: A systematic review and updated meta-analysis. Cancers (Basel). 12:18992020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, Wang Y, Zhang Z, Yuan T, Ding X, et al: Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 11:63222020. View Article : Google Scholar : PubMed/NCBI | |
|
Rizzo A, Pantaleo MA, Saponara M and Nannini M: Current status of the adjuvant therapy in uterine sarcoma: A literature review. World J Clin Cases. 7:1753–1763. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, Marchetti A, Battelli N and Massari F: The impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol. 170:1035962022. View Article : Google Scholar : PubMed/NCBI | |
|
Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M and Eshhar Z: Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol. 151:6577–6582. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368:1509–1518. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Wu L, Huang C, Liu R, Li Z, Liu L and Shan B: Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors-a narrative review. Ann Transl Med. 8:10932020. View Article : Google Scholar : PubMed/NCBI | |
|
Abbas MZ: Strategic use of patent opposition safeguard to improve equitable access to innovative health technologies: A case study of CAR T-cell therapy Kymriah. Glob Public Health. 17:3255–3265. 2022. View Article : Google Scholar | |
|
Astolfi A, Nannini M, Indio V, Schipani A, Rizzo A, Perrone AM, De Iaco P, Pirini MG, De Leo A, Urbini M, et al: Genomic database analysis of uterine leiomyosarcoma mutational profile. Cancers (Basel). 12:21262020. View Article : Google Scholar : PubMed/NCBI | |
|
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, et al: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. Lancet. 398:314–324. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, Teruya-Feldstein J, Crary JF, Fowkes ME, Stacy CB, et al: Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 27:2099–2103. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, et al: Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 380:1726–1737. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, et al: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 4:e1276842018. View Article : Google Scholar | |
|
Guo B, Chen M, Han Q, Hui F, Dai H, Zhang W, Zhang Y, Wang Y, Zhu H and Han W: CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immunother. 2:28–35. 2016. View Article : Google Scholar | |
|
Zhu J, Simayi N, Wan R and Huang W: CAR T targets and microenvironmental barriers of osteosarcoma. Cytotherapy. 24:567–576. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Boettcher M, Joechner A, Li Z, Yang SF and Schlegel P: Development of CAR T cell therapy in children-A comprehensive overview. J Clin Med. 11:21582022. View Article : Google Scholar : PubMed/NCBI | |
|
Sadelain M, Brentjens R and Rivière I: The basic principles of chimeric antigen receptor design. Cancer Discv. 3:388–398. 2013. View Article : Google Scholar | |
|
Morita R, Nishizawa S, Torigoe T, Takahashi A, Tamura Y, Tsukahara T, Kanaseki T, Sokolovskaya A, Kochin V, Kondo T, et al: Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells. Cancer Sci. 105:389–395. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al: Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 33:1688–1696. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Picarda E, Ohaegbulam KC and Zang X: Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 22:3425–3431. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Yu W, Zhu J, Wang J, Xia K, Liang C and Tao H: Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J Exp Clin Cancer Res. 38:1682019. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu K, Middlemiss S, Saletta F, Gottschalk S, McCowage GB and Kramer B: Chimeric antigen receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther. 28:321–334. 2021. View Article : Google Scholar : | |
|
Reppel L, Tsahouridis O, Akulian J, Davis IJ, Lee H, Fucà G, Weiss J, Dotti G, Pecot CV and Savoldo B: Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. J Immunother Cancer. 10:e0038972022. View Article : Google Scholar : PubMed/NCBI | |
|
Huang G, Yu L, Cooper LJN, Hollomon M, Huls H and Kleinerman ES: Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 72:271–281. 2012. View Article : Google Scholar | |
|
Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, et al: IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas. PLoS One. 10:e01331522015. View Article : Google Scholar : PubMed/NCBI | |
|
Fernández L, Metais JY, Escudero A, Vela M, Valentín J, Vallcorba I, Leivas A, Torres J, Valeri A, Patiño-García A, et al: Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells. Clin Cancer Res. 23:5824–5835. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Riccardo F, Tarone L, Iussich S, Giacobino D, Arigoni M, Sammartano F, Morello E, Martano M, Gattino F, Maria R, et al: Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. Ther Adv Med Oncol. 11:17588359198554912019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Ding C, Wang J, Sun G, Cao Y, Xu L, Zhou L and Chen X: Prognostic significance of CD44V6 expression in osteosarcoma: A meta-analysis. J Orthop Surg Res. 10:1872015. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Z, Wu Z and Luo W: Chimeric antigen receptor T-cell therapy: The light of day for osteosarcoma. Cancers (Basel). 13:44692021. View Article : Google Scholar : PubMed/NCBI | |
|
Shah NN and Fry TJ: Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 16:372–385. 2019.PubMed/NCBI | |
|
Guan Y, Zhang R, Peng Z, Dong D, Wei G and Wang Y: Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer. J Bone Oncol. 9:59–64. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K and Guo W: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 11:162018. View Article : Google Scholar : PubMed/NCBI | |
|
Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, June C, Kaiser LR, Ling LE and Albelda SM: Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res. 14:3966–3974. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fedorov VD, Themeli M and Sadelain M: PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 5:215ra1722013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen JC, Chang YW, Hong CC, Yu YH and Su JL: The role of the VEGF-C/VEGFRs axis in tumor progression and therapy. Int J Mol Sci. 14:88–107. 2012. View Article : Google Scholar | |
|
Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH and Brentjens RJ: Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23:2130–2141. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Smith TT, Moffett HF, Stephan SB, Opel CF, Dumigan AG, Jiang X, Pillarisetty VG, Pillai SPS, Wittrup KD and Stephan MT: Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest. 127:2176–2191. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xia T, Konno H and Barber GN: Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis. Cancer Res. 76:6747–6759. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK and Sadelain M: Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther. 26:2542–2552. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chulanetra M, Morchang A, Sayour E, Eldjerou L, Milner R, Lagmay J, Cascio M, Stover B, Slayton W, Chaicumpa W, et al: GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas. Am J Cancer Res. 10:674–687. 2020.PubMed/NCBI | |
|
Buka D, Dvořák J, Sitorová V, Hátlová J, Richter I and Sirák I: Changes in the CD8+ density of tumor infiltrating lymphocytes after neoadjuvant radiochemotherapy in patients with rectal adenocarcinom. Klin Onkol. 29:204–209. 2016.In Czech. View Article : Google Scholar | |
|
Makita S, Imaizumi K, Kurosawa S and Tobinai K: Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: Opportunities and challenges. Drugs Context. 8:2125672019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Zhu L, Zhang H, Chen S and Xiao Y: CAR-T cell therapy in hematological malignancies: Current opportunities and challenges. Front Immunol. 13:9271532022. View Article : Google Scholar : PubMed/NCBI | |
|
Kong Y, Tang L, You Y, Li Q and Zhu X: Analysis of causes for poor persistence of CAR-T cell therapy in vivo. Front Immunol. 14:10634542023. View Article : Google Scholar : PubMed/NCBI | |
|
Asmamaw Dejenie T, Tiruneh G/Medhin M, Dessie Terefe G, Tadele Admasu F, Wale Tesega W and Chekol Abebe E: Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccin Immunother. 18:21142542022. View Article : Google Scholar : PubMed/NCBI | |
|
Farkona S, Diamandis EP and Blasutig IM: Cancer immunotherapy: The beginning of the end of cancer? BMC Med. 14:732016. View Article : Google Scholar : PubMed/NCBI | |
|
García Merino A: Anticuerpos monoclonales. Aspectos básicos. Neurología. 26:301–306. 2011. View Article : Google Scholar | |
|
Lu J, Ding J, Liu Z and Chen T: Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (review). Int J Oncol. 60:122022. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, et al: Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 17:1779–1787. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM and Brenner MK: A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 12:933–941. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada R, Takahashi A, Torigoe T, Morita R, Tamura Y, Tsukahara T, Kanaseki T, Kubo T, Watarai K, Kondo T, et al: Preferential expression of cancer/testis genes in cancer stem-like cells: Proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens. 81:428–434. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, Kanaseki T, Kamiguchi K, Asanuma H, Morita R, et al: HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res. 72:2844–2854. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe Y, Tsukahara T, Murata K, Hamada S, Kubo T, Kanaseki T, Hirohashi Y, Emori M, Teramoto A, Nakatsugawa M, et al: Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours. Br J Cancer. 128:886–895. 2023. View Article : Google Scholar : | |
|
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Abdou AG, Kandil M, Asaad NY, Dawoud MM, Shahin AA and Abd Eldayem AF: The prognostic role of Ezrin and HER2/neu expression in osteosarcoma. Appl Immunohistochem Mol Morphol. 24:355–363. 2016. View Article : Google Scholar | |
|
Xuan Y, Sheng Y, Zhang D, Zhang K, Zhang Z, Ping Y, Wang S, Shi X, Lian J, Liu K, et al: Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models. Transl Oncol. 14:1011382021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, He L, Sadagopan A, Ma T, Dotti G, Wang Y, Zheng H, Gao X, Wang D, DeLeo AB, et al: Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells. Mol Cancer Ther. 20:577–588. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, et al: Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 35:221–237.e8. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, Labanieh L, Dhingra S, Leruste A, Majzner RG, et al: Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat Med. 26:712–719. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Talbot LJ, Chabot A, Funk A, Nguyen P, Wagner J, Ross A, Tillman H, Davidoff A, Gottschalk S and DeRenzo C: A novel orthotopic implantation technique for osteosarcoma produces spontaneous metastases and illustrates dose-dependent efficacy of B7-H3-CAR T cells. Front Immunol. 12:6917412021. View Article : Google Scholar : PubMed/NCBI | |
|
Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, et al: CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 25:2560–2574. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Swart GWM: Activated leukocyte cell adhesion molecule (CD166/ALCAM): Developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 81:313–321. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, Liu B, Marks JD and Denny CT: Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012:1269062012. View Article : Google Scholar : PubMed/NCBI | |
|
He S, Li S, Guo J, Zeng X, Liang D, Zhu Y, Li Y, Yang D and Zhao X: CD166-specific CAR-T cells potently target colorectal cancer cells. Transl Oncol. 27:1015752023. View Article : Google Scholar | |
|
Kang BH, Jensen KJ, Hatch JA and Janes KA: Simultaneous profiling of 194 distinct receptor transcripts in human cells. Sci Signal. 6:rs132013. View Article : Google Scholar : PubMed/NCBI | |
|
Pasquale EB: Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer. 10:165–180. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wykosky J and Debinski W: The EphA2 receptor and ephrinA1 ligand in solid tumors: Function and therapeutic targeting. Mol Cancer Res. 6:1795–1806. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fritsche-Guenther R, Noske A, Ungethüm U, Kuban RJ, Schlag PM, Tunn PU, Karle J, Krenn V, Dietel M and Sers C: De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology. 57:836–850. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Doronin II, Vishnyakova PA, Kholodenko IV, Ponomarev ED, Ryazantsev DY, Molotkovskaya IM and Kholodenko RV: Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer. 14:2952014. View Article : Google Scholar : PubMed/NCBI | |
|
Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, Gill J and Gorlick R: Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 120:548–554. 2014. View Article : Google Scholar | |
|
Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, El-Etriby R, Galli S, Tsokos MG, Orentas RJ and Mackall CL: Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol Res. 4:869–880. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Suri M, Soni N, Okpaleke N, Yadav S, Shah S, Iqbal Z, Alharbi MG, Kalra HS and Hamid P: A deep dive into the newest avenues of immunotherapy for pediatric osteosarcoma: A systematic review. Cureus. 13:e183492021.PubMed/NCBI | |
|
Park JA and Cheung NKV: GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. J Hematol Oncol. 13:1722020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang J, Wang R, Yang L, Sha Y, Zhao S, Guo J, Chen D, Zhong Z and Meng F: IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma. J Control Release. 350:460–470. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lokau J, Schoeder V and Garbers C: The role of interleukin-11 in osteosarcoma. Der Pathologe. 41:163–167. 2020.In German. View Article : Google Scholar | |
|
Li YS, Liu Q, He HB and Luo W: The possible role of insulin-like growth factor-1 in osteosarcoma. Curr Probl Cancer. 43:228–235. 2019. View Article : Google Scholar | |
|
Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H and Hornicek FJ: Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther. 8:2122–2130. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tan X, Fan S, Wu W and Zhang Y: MicroRNA-26a inhibits osteosarcoma cell proliferation by targeting IGF-1. Bone Res. 3:150332015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zhu ST, Wang X, Deng J, Li WH, Zhang P and Liu BS: MiR-100 inhibits osteosarcoma cell proliferation, migration, and invasion and enhances chemosensitivity by targeting IGFIR. Technol Cancer Res Treat. 15:NP40–NP48. 2016. View Article : Google Scholar | |
|
Chen G, Fang T, Huang Z, Qi Y, Du S, Di T, Lei Z, Zhang X and Yan W: MicroRNA-133a inhibits osteosarcoma cells proliferation and invasion via targeting IGF-1R. Cell Physiol Biochem. 38:598–608. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A and Mellstedt H: The receptor tyrosine kinase ROR1-an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 29:21–31. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dai B, Shen Y, Yan T and Zhang A: Wnt5a/ROR1 activates DAAM1 and promotes the migration in osteosarcoma cells. Oncol Rep. 43:601–608. 2020.PubMed/NCBI | |
|
Zhang T, Barber A and Sentman CL: Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 66:5927–5933. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ding H, Yang X and Wei Y: Fusion proteins of NKG2D/NKG2DL in cancer immunotherapy. Int J Mol Sci. 19:1772018. View Article : Google Scholar : PubMed/NCBI | |
|
Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, et al: Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol Res. 7:100–112. 2019. View Article : Google Scholar | |
|
Tao K, He M, Tao F, Xu G, Ye M, Zheng Y and Li Y: Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. Cancer Chemother Pharmacol. 82:815–827. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Li X, Zhang J and Mao L: Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer. Biomed Pharmacother. 131:1105622020. View Article : Google Scholar : PubMed/NCBI | |
|
Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, Li W, Cai C, Xu J and Zhao X: Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res. 7:1813–1823. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli MR, et al: CSPG4 in cancer: multiple roles. Curr Mol Med. 10:419–429. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rolih V, Barutello G, Iussich S, De Maria R, Quaglino E, Buracco P, Cavallo F and Riccardo F: CSPG4: A prototype oncoantigen for translational immunotherapy studies. J Transl Med. 15:1512017. View Article : Google Scholar : PubMed/NCBI | |
|
Casanova JM, Almeida JS, Reith JD, Sousa LM, Fonseca R, Freitas-Tavares P, Santos-Rosa M and Rodrigues-Santos P: Tumor-infiltrating lymphocytes and cancer markers in osteosarcoma: Influence on patient survival. Cancers (Basel). 13:60752021. View Article : Google Scholar : PubMed/NCBI | |
|
Deng Z, Niu G, Cai L, Wei R and Zhao X: The prognostic significance of CD44V6, CDH11, and β-catenin expression in patients with osteosarcoma. Biomed Res Int. 2013:4961932013. View Article : Google Scholar | |
|
Qiao GL, Song LN, Deng ZF, Chen Y and Ma LJ: Prognostic value of CD44v6 expression in breast cancer: A meta-analysis. Onco Targets Ther. 11:5451–5457. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Saito S, Okabe H, Watanabe M, Ishimoto T, Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y and Baba H: CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncol Rep. 29:1570–1578. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nakajima K, Taniguchi K and Mutoh KI: Expression of CD44v6 as matrix-associated ectodomain in the bone development. J Vet Med Sci. 72:1017–1022. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z and Qian Q: Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 15:2548–2560. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Yan L and Zhou M: Target selection of CAR T cell therapy in accordance with the TME for solid tumors. Am J Cancer Res. 9:228–241. 2019.PubMed/NCBI | |
|
Saifullah MK, Fox DA, Sarkar S, Abidi SM, Endres J, Piktel J, Haqqi TM and Singer NG: Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues. J Immunol. 173:6125–6133. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda K and Quertermous T: Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function. J Biol Chem. 279:55315–55323. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Zhang Z, Liu G, Li D, Gu Z, Zhang L, Pan Y, Cui X, Wang L, Liu G, et al: B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. BMC Cancer. 22:11242022. View Article : Google Scholar : PubMed/NCBI | |
|
Majzner RG, Heitzeneder S and Mackall CL: Harnessing the immunotherapy revolution for the treatment of childhood cancers. Cancer Cell. 31:476–485. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM and Vera JF: Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 25:249–258. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson KG, Stromnes IM and Greenberg PD: Obstacles posed by the tumor microenvironment to T cell activity: A case for synergistic therapies. Cancer Cell. 31:311–325. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner LM and Adams VR: Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. Onco Targets Ther. 10:2097–2106. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hashimoto K, Nishimura S and Akagi M: Characterization of PD-1/PD-L1 immune checkpoint expression in osteosarcoma. Diagnostics (Basel). 10:5282020. View Article : Google Scholar : PubMed/NCBI | |
|
Kawano M, Itonaga I, Iwasaki T and Tsumura H: Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Oncol Rep. 29:1001–1006. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lussier DM, Johnson JL, Hingorani P and Blattman JN: Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer. 3:212015. View Article : Google Scholar | |
|
Sun CY, Zhang Z, Tao L, Xu FF, Li HY, Zhang HY and Liu W: T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 9:14472021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Luo J, Li Y, Cao J and Wang X: IFNγ and TNFα synergistically promote galectin 9 secretion by human osteosarcoma cells MG-63 to prevent T cell killing. Int J Clin Exp Pathol. 13:2009–2017. 2020. | |
|
Sterner RC and Sterner RM: CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 11:692021. View Article : Google Scholar : PubMed/NCBI | |
|
Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hattinger CM, Salaroglio IC, Fantoni L, Godel M, Casotti C, Kopecka J, Scotlandi K, Ibrahim T, Riganti C and Serra M: Strategies to overcome resistance to immune-based therapies in osteosarcoma. Int J Mol Sci. 24:7992023. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Q, Liang X, Ren T, Huang Y, Zhang H, Yu Y, Chen C, Wang W, Niu J, Lou J and Guo W: The role of tumor-associated macrophages in osteosarcoma progression-therapeutic implications. Cell Oncol (Dordr). 44:525–539. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Dumars C, Ngyuen JM, Gaultier A, Lanel R, Corradini N, Gouin F, Heymann D and Heymann MF: Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. Oncotarget. 7:78343–78354. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sugiyama D, Hinohara K and Nishikawa H: Significance of regulatory T cells in cancer immunology and immunotherapy. Exp Dermatol. 32:256–263. 2023. View Article : Google Scholar | |
|
Taylor A, Verhagen J, Blaser K, Akdis M and Akdis CA: Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: The role of T regulatory cells. Immunology. 117:433–442. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Law AMK, Valdes-Mora F and Gallego-Ortega D: Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 9:5612020. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao H, Chen L, Luo G, Son H, Prectoni JH and Zheng W: Effect of the cytokine levels in serum on osteosarcoma. Tumor Biol. 35:1023–1028. 2014. View Article : Google Scholar | |
|
Tian B, Du X, Zheng S and Zhang Y: The role of tumor microenvironment in regulating the plasticity of osteosarcoma cells. Int J Mol Sci. 23:161552022. View Article : Google Scholar : PubMed/NCBI | |
|
Lamora A, Talbot J, Bougras G, Amiaud J, Leduc M, Chesneau J, Taurelle J, Stresing V, Le Deley MC, Heymann MF, et al: Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma. Clin Cancer Res. 20:5097–5112. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shen L, Li J, Liu Q, Song W, Zhang X, Tiruthani K, Hu H, Das M, Goodwin TJ, Liu R and Huang L: Local blockade of interleukin 10 and C-X-C motif chemokine ligand 12 with nano-delivery promotes antitumor response in murine cancers. ACS Nano. 12:9830–9841. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rossowska J, Anger N, Szczygieł A, Mierzejewska J and Pajtasz-Piasecka E: Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy. J Exp Clin Cancer Res. 37:1262018. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng J, Chen S, Li C, Ye Z, Lin B, Liang Y, Wang B, Ma Y, Chai X, Zhang X, et al: Mesenchymal stem/stromal cells-derived IL-6 promotes nasopharyngeal carcinoma growth and resistance to cisplatin via upregulating CD73 expression. J Cancer. 11:2068–2079. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang C, Tian Y, Zhao F, Chen Z, Su P, Li Y and Qian A: Bone microenvironment and osteosarcoma metastasis. Int J Mol Sci. 21:69852020. View Article : Google Scholar : PubMed/NCBI | |
|
Chang AI, Schwertschkow AH, Nolta JA and Wu J: Involvement of mesenchymal stem cells in cancer progression and metastases. Curr Cancer Drug Targets. 15:88–98. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pietrovito L, Leo A, Gori V, Lulli M, Parri M, Becherucci V, Piccini L, Bambi F, Taddei ML and Chiarugi P: Bone marrow-derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition. Mol Oncol. 12:659–676. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lugano R, Ramachandran M and Dimberg A: Tumor angiogenesis: Causes, consequences, challenges and opportunities. Cell Mol Life Sci. 77:1745–1770. 2020. View Article : Google Scholar : | |
|
Tsukamoto S, Honoki K, Fujii H, Tohma Y, Kido A, Mori T, Tsujiuchi T and Tanaka Y: Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Int J Oncol. 40:163–169. 2012. | |
|
Zhang R, Liu Q, Zhou S, He H, Zhao M and Ma W: Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1. Elife. 12:e829342023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Song J, Xin X, Sun D, Huang H, Chen Y, Zhang T and Zhang Y: Hypoxia stimulates the migration and invasion of osteosarcoma via up-regulating the NUSAP1 expression. Open Med (Wars). 16:1083–1089. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Lv X, Li J, Zhang C, Hu T, Li S, He S, Yan H, Tan Y, Lei M, Wen M and Zuo J: The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. Genes Dis. 4:19–24. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Guan G, Zhang Y, Lu Y, Liu L, Shi D, Wen Y, Yang L, Ma Q, Liu T, Zhu X, et al: The HIF-1α/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells. Cancer Lett. 357:254–264. 2015. View Article : Google Scholar | |
|
Liu M, Wang D and Li N: MicroRNA-20b downregulates HIF-1α and inhibits the proliferation and invasion of osteosarcoma cells. Oncol Res. 23:257–266. 2016. View Article : Google Scholar | |
|
Galon J and Bruni D: Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 18:197–218. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
de la Cruz-López KG, Castro-Muñoz LJ, Reyes-Hernández DO, García-Carrancá A and Manzo-Merino J: Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol. 9:11432019. View Article : Google Scholar : PubMed/NCBI | |
|
Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J and Riganti C: Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat. 59:1007872021. View Article : Google Scholar : PubMed/NCBI | |
|
Avnet S, Di Pompo G, Chano T, Errani C, Ibrahim-Hashim A, Gillies RJ, Donati DM and Baldini N: Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation. Int J Cancer. 140:1331–1345. 2017. View Article : Google Scholar : | |
|
Bobulescu IA, Di Sole F and Moe OW: Na+/H+ exchangers: Physiology and link to hypertension and organ ischemia. Curr Opin Nephrol Hypertens. 14:485–494. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Swietach P, Vaughan-Jones RD and Harris AL: Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26:299–310. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chiche J, Brahimi-Horn MC and Pouysségur J: Tumor hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med. 14:771–794. 2010. View Article : Google Scholar | |
|
Yang Q, Liu J, Wu B, Wang X, Jiang Y and Zhu D: Role of extracellular vesicles in osteosarcoma. Int J Med Sci. 19:1216–1226. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Xie L, Ren T, Huang Y, Xu J and Guo W: Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 500:1–10. 2021. View Article : Google Scholar | |
|
Prudowsky ZD and Yustein JT: Recent insights into therapy resistance in osteosarcoma. Cancers (Basel). 13:832020. View Article : Google Scholar | |
|
Xie J, Wu H, Dai C, Pan Q, Ding Z, Hu D, Ji B, Luo Y and Hu X: Beyond Warburg effect-dual metabolic nature of cancer cells. Sci Rep. 4:49272014. View Article : Google Scholar | |
|
Tang HY, Guo JQ, Sang BT, Cheng JN and Wu XM: PDGFRβ modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K/AKT/mTOR/c-Myc pathway. Biochem Cell Biol. 100:75–84. 2022. View Article : Google Scholar | |
|
Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, et al: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res. 65:3044–3048. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rodríguez PC and Ochoa AC: Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol Rev. 222:180–191. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Pietrobon V and Marincola FM: Hypoxia and the phenomenon of immune exclusion. J Transl Med. 19:92021. View Article : Google Scholar : PubMed/NCBI | |
|
Patel CH and Powell JD: Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease. Curr Opin Immunol. 46:82–88. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Muller-Tidow C and Dreger P: Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 32:34–48. 2021. View Article : Google Scholar | |
|
Almåsbak H, Aarvak T and Vemuri MC: CAR T cell therapy: A game changer in cancer treatment. J Immunol Res. 2016:54746022016. View Article : Google Scholar : PubMed/NCBI | |
|
Maus MV, Grupp SA, Porter DL and June CH: Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 123:2625–2635. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, López-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP and Rao A: NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 567:530–534. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Klebanoff CA, Gattinoni L and Restifo NP: Sorting through subsets: Which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 35:651–660. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang BL, Qin DY, Mo ZM, Li Y, Wei W, Wang YS, Wang W and Wei YQ: Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Sci China Life Sci. 59:340–348. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM and Hwu P: Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 13:1971–1980. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, et al: Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6:80–95. 2016. View Article : Google Scholar : | |
|
Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, et al: Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 110:20212–20217. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xia AL, Wang XC, Lu YJ, Lu XJ and Sun B: Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: Challenges and opportunities. Oncotarget. 8:90521–90531. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tian M, Cheuk AT, Wei JS, Abdelmaksoud A, Chou HC, Milewski D, Kelly MC, Song YK, Dower CM, Li N, et al: An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma. J Clin Invest. 132:e1556212022. View Article : Google Scholar : PubMed/NCBI | |
|
Muhammad N, Wang R, Li W, Zhang Z, Chang Y, Hu Y, Zhao J, Zheng X, Mao Q and Xia H: A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy. Mol Ther Oncolytics. 24:729–741. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Han X, Wang Y, Wei J and Han W: Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol. 12:1282019. View Article : Google Scholar : PubMed/NCBI | |
|
Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC and Riddell SR: The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 3:125–135. 2015. View Article : Google Scholar | |
|
Srivastava S and Riddell SR: Engineering CAR-T cells: Design concepts. Trends Immunol. 36:494–502. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Künkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS and Jensen MC: Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell fas-FasL-dependent AICD. Cancer Immunol Res. 3:368–379. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ and Press OW: Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 180:7028–7038. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM and Maher J: Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor. J Immunol. 180:4901–4909. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C and Riddell SR: Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 19:3153–3164. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, et al: The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens. J Immunother. 28:203–211. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, et al: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 26:270–280. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJW, Sievers SA, Yang S and Kochenderfer JN: Function of novel Anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 25:2452–2465. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hombach A, Hombach AA and Abken H: Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther. 17:1206–1213. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G and Kyte JA: Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 22:391–403. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM and Vera JF: Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 5:e12536562016. View Article : Google Scholar | |
|
Stoiber S, Cadilha BL, Benmebarek MR, Lesch S, Endres S and Kobold S: Limitations in the design of chimeric antigen receptors for cancer therapy. Cells. 8:4722019. View Article : Google Scholar : PubMed/NCBI | |
|
Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M and Gilham DE: The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol. 184:6938–6949. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, et al: Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight. 3:e969762018. View Article : Google Scholar : PubMed/NCBI | |
|
Wan Z, Shao X, Ji X, Dong L, Wei J, Xiong Z, Liu W and Qi H: Transmembrane domain-mediated Lck association underlies bystander and costimulatory ICOS signaling. Cell Mol Immunol. 17:143–152. 2020. View Article : Google Scholar : | |
|
Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber EW, Tousley AM, et al: Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10:702–723. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M and Okada N: Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold. Cells. 9:11822020. View Article : Google Scholar : PubMed/NCBI | |
|
Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, Shi M, Lan J, Fei X, Jin L, et al: A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial. Lancet Haematol. 6:e521–e529. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Gao L, Wen Q, Zhong JF, Zhang C and Zhang X: Recent advances in CAR-T cell engineering. J Hematol Oncol. 13:862020. View Article : Google Scholar : PubMed/NCBI | |
|
Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL and Campana D: Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 18:676–684. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Song DG, Ye Q, Poussin M, Harms GM, Figini M and Powell DJ Jr: CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 119:696–706. 2012. View Article : Google Scholar | |
|
Maher J, Brentjens RJ, Gunset G, Riviere I and Sadelain M: Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 20:70–75. 2002. View Article : Google Scholar | |
|
Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, et al: ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood. 124:1070–1080. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mullard A: FDA approves first CAR T therapy. Nat Rev Drug Discov. 16:6692017. | |
|
Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, et al: Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 106:3360–3365. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J and Sadelain M: Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 28:415–428. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Guedan S, Madar A, Casado-Medrano V, Shaw C, Wing A, Liu F, Young RM, June CH and Posey AD Jr: Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. J Clin Invest. 130:3087–3097. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
van der Merwe PA and Dushek O: Mechanisms for T cell receptor triggering. Nat Rev Immunol. 11:47–55. 2011. View Article : Google Scholar | |
|
Gaud G, Lesourne R and Love PE: Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol. 18:485–497. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M and Sadelain M: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med. 25:82–88. 2019. View Article : Google Scholar : | |
|
James JR: Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand density. Sci Signal. 11:eaan10882018. View Article : Google Scholar : PubMed/NCBI | |
|
Bachiller M, Dobaño-López C, Rodríguez-García A, Castellsagué J, Gimenez-Alejandre M, Antoñana-Vildosola A, Martin-Antonio B, Delgado J, Pérez-Galán P, Juan M, et al: Co-Transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-hodgkin lymphoma. Blood. 140(Suppl 1): S7386–S7387. 2022. View Article : Google Scholar | |
|
Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Oporto-Espuelas M, Yeung J, Pinner D, Chu J, Williams L, et al: Dual antigen targeting with co-transduced CD19/22 CAR T cells may prevent antigen-negative relapse after CAR T cell therapy for relapsed/refractory ALL. Blood. 140(Suppl 1): S10352–S10354. 2022. View Article : Google Scholar | |
|
Wang L, Tan Su Yin E, Zhao H, Ni F, Hu Y and Huang H: CAR-T cells: The Chinese experience. Expert Opin Biol Ther. 20:1293–1308. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sun C, Dotti G and Savoldo B: Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood. 127:3350–3359. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dhupkar P, Gordon N, Stewart J and Kleinerman ES: Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. 7:2654–2664. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al: Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 36:847–856. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kenderian SS, Ruella M, Shestova O, Klichinsky M, Kim M, Porter DL, June CH and Gill S: Identification of PD1 and TIM3 As checkpoints that limit chimeric antigen receptor T cell efficacy in leukemia. Biol Blood Marrow Transplant. 22(3 Suppl): S19–S21. 2016. View Article : Google Scholar | |
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR and Albelda SM: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin MR and Umansky V: Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma mode. J Immunol. 190:2464–2471. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Eriksson E, Wenthe J, Irenaeus S, Loskog A and Ullenhag G: Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med. 14:2822016. View Article : Google Scholar | |
|
Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kübler H, Yancey D, Dahm P and Vieweg J: Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 14:8270–8278. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida K, Okamoto M, Sasaki J, Kuroda C, Ishida H, Ueda K, Ideta H, Kamanaka T, Sobajima A, Takizawa T, et al: Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer. 20:252020. View Article : Google Scholar : PubMed/NCBI | |
|
Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, et al: CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 19:1264–1272. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et al: Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 24:589–602. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nadella V, Singh S, Jain A, Jain M, Vasquez KM, Sharma A, Tanwar P, Rath GK and Prakash H: Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium. Mol Carcinog. 57:1664–1671. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH and Gill S: Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells. Cancer Discov. 7:1154–1167. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Choi SH, Myers J, Tomchuck S, Bonner M, Eid S, Kingsley D, VanHeyst K, Kim SJ, Kim BG and Huang AY: Oral TGF-βR1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity. Res Sq. rs.3.rs-27092822023. | |
|
Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, Wei XF, Han W and Wang H: TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 5:e1339772020. View Article : Google Scholar | |
|
Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, Balyasnikova IV and Gottschalk S: Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 5:571–581. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chmielewski M, Kopecky C, Hombach AA and Abken H: IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71:5697–5706. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Loschinski R, Böttcher M, Stoll A, Bruns H, Mackensen A and Mougiakakos D: IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner. Oncotarget. 9:13125–13138. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Y, Si X, Shao M, Teng X, Xiao G and Huang H: Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. J Hematol Oncol. 15:382022. View Article : Google Scholar : PubMed/NCBI | |
|
Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, et al: Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest. 123:4479–4488. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, Kogadeeva M, Picotti P, Meissner F, Mann M, et al: L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 167:829–842.e13. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ghassemi S, Martinez-Becerra FJ, Master AM, Richman SA, Heo D, Leferovich J, Tu Y, García-Cañaveras JC, Ayari A, Lu Y, et al: Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design. Mol Ther Methods Clin Dev. 18:595–606. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet. 385:517–528. 2015. View Article : Google Scholar | |
|
Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et al: Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 8:355ra1162016. View Article : Google Scholar : PubMed/NCBI | |
|
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 6:224ra252014. View Article : Google Scholar : PubMed/NCBI | |
|
Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H and Hudecek M: The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 11:eaau59072019. View Article : Google Scholar : PubMed/NCBI | |
|
Varadarajan I and Lee DW: Management of T-cell engaging immunotherapy complications. Cancer J. 25:223–230. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK and Seed B: Tumor induction of VEGF promoter activity in stromal cells. Cell. 94:715–725. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP and Rosenberg SA: Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 120:3953–3968. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Ma Y, Li J, Shi HS, Wang LQ, Guo FC, Zhang J, Li D, Mo BH, Wen F, et al: Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther. 20:970–978. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Slaney CY, Kershaw MH and Darcy PK: Trafficking of T cells into tumors. Cancer Res. 74:7168–7174. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
van Schalkwyk MC, Papa SE, Jeannon JP, Guerrero Urbano T, Spicer JF and Maher J: Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurre head and neck cancer. Hum Gene Ther Clin Dev. 24:134–142. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sridhar P and Petrocca F: Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy. Cancers (Basel). 9:922017. View Article : Google Scholar : PubMed/NCBI | |
|
Milner JJ, Toma C, Yu B, Zhang K, Omilusik K, Phan AT, Wang D, Getzler AJ, Nguyen T, Crotty S, et al: Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumors. Nature. 552:253–257. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D and Dotti G: Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 21:524–529. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM and Foster AE: Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 33:780–788. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M and June CH: T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 1:26–31. 2013. View Article : Google Scholar | |
|
Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, et al: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 112:2261–2271. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ajina A and Maher J: Prospects for combined use of oncolytic viruses and CAR T-cells. Review. J Immunother Cancer. 5:902017. View Article : Google Scholar | |
|
Kim DS, Dastidar H, Zhang C, Zemp FJ, Lau K, Ernst M, Rakic A, Sikdar S, Rajwani J, Naumenko V, et al: Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. Nat Commun. 8:3442017. View Article : Google Scholar : PubMed/NCBI | |
|
Scott EM, Duffy MR, Freedman JD, Fisher KD and Seymour LW: Solid tumor immunotherapy with T cell engager-armed oncolytic viruses. Macromol Biosci. 18:17001872018. View Article : Google Scholar | |
|
Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y and Moon EK: A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 76:1578–1590. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chmielewski M and Abken H: TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation. Adv Cell Gene Ther. 3:e842020. View Article : Google Scholar | |
|
Zhang H, Zhao P and Huang H: Engineering better chimeric antigen receptor T cells. Exp Hematol Oncol. 9:342020. View Article : Google Scholar : PubMed/NCBI | |
|
Köksal H, Müller E, Inderberg EM, Bruland Ø and Wälchli S: Treating osteosarcoma with CAR T cells. Scand J Immunol. 89:e127412019. View Article : Google Scholar | |
|
Noordam L, Kaijen MEH, Bezemer K, Cornelissen R, Maat LAPWM, Hoogsteden HC, Aerts JGJV, Hendriks RW, Hegmans JPJJ and Vroman H: Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. Oncoimmunology. 7:e14743182018. View Article : Google Scholar | |
|
Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, et al: Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome. Cancer Immunol Immunother. 61:353–362. 2012. View Article : Google Scholar | |
|
Hu J, Sun C, Bernatchez C, Xia X, Hwu P, Dotti G and Li S: T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors. Clin Cancer Res. 24:2920–2934. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, Katsanis E and Larmonier N: Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 74:104–118. 2014. View Article : Google Scholar | |
|
Seliger B and Quandt D: The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother. 61:1327–1341. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Murad JP, Tilakawardane D, Park AK, Lopez LS, Young CA, Gibson J, Yamaguchi Y, Lee HJ, Kennewick KT, Gittins BJ, et al: Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol Ther. 29:2335–2349. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kohli K, Pillarisetty VG and Kim TS: Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 29:10–21. 2022. View Article : Google Scholar : | |
|
Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, Garrison SM, Specht JM, Lee SM, Amezquita RA, et al: Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell. 39:193–208.e10. 2021. View Article : Google Scholar | |
|
Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes CF, et al: Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell. 103:491–500. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E and Gabrilovich DI: Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 72:5483–5493. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Trapani JA, Sutton VR, Thia KYT, Li YQ, Froelich CJ, Jans DA, Sandrin MS and Browne KA: A clathrin/dynaminand mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death. J Cell Biol. 160:223–233. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Parente-Pereira AC, Whilding LM, Brewig N, van der Stegen SJ, Davies DM, Wilkie S, van Schalkwyk MC, Ghaem-Maghami S and Maher J: Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-Retargeted T cells combined with carboplatin. J Immunol. 191:2437–2445. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Proietti E, Moschella F, Capone I and Belardelli F: Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Mol Oncol. 6:1–14. 2012. View Article : Google Scholar | |
|
Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al: An immunosurveillance mechanism controls cancer cell ploidy. Science. 337:1678–1684. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, Séror C, Métivier D, Perfettini JL, Zitvogel L and Kroemer G: Chemotherapy induces ATP release from tumor cells. Cell Cycle. 8:3723–3728. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al: Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 6:5882015. View Article : Google Scholar : PubMed/NCBI | |
|
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, et al: Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 20:1301–1309. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vierboom MP, Bos GM, Ooms M, Offringa R and Melief CJ: Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer. 87:253–260. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Higgins JP, Bernstein MB and Hodge JW: Enhancing immune responses to tumor-associated antigens. Cancer Biol Ther. 8:1440–1449. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I and Lecanda F: Radiation effects on antitumor immune responses: Current perspectives and challenges. Ther Adv Med Oncol. 10:17588340177425752018. View Article : Google Scholar : PubMed/NCBI | |
|
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 13:1050–1059. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Crouse J, Kalinke U and Oxenius A: Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 15:231–242. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX and Auh SL: The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 71:2488–2496. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, et al: Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 208:1989–2003. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM and Gajewski TF: Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med. 208:2005–2016. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Weiss T, Weller M, Guckenberger M, Sentman CL and Roth P: NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 78:1031–1043. 2018. View Article : Google Scholar | |
|
Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti SC, Dustin ML and Demaria S: Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 181:3099–3107. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, et al: Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 204:49–55. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ganss R, Ryschich E, Klar E, Arnold B and Hämmerling GJ: Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62:1462–1470. 2002.PubMed/NCBI | |
|
Yovino S and Grossman SA: Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol. 1:149–154. 2012. View Article : Google Scholar |
